Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercetin supplementation may be beneficial in treating COPD, key methodological issues have not been resolved. The overall objective of this study is to determine the dosage of quercetin supplementation, bioavailability of quercetin, safety, dose-response relationship and appropriate biomarkers which reflect clinical outcomes in patients with COPD that is necessary for conducting large clinical trials in this patient population.

Key facts

Study ID

NCT01708278

Run by

University of Michigan

People needed

9

Starts

2014-02-01

Expected to finish

2015-10-01

Last updated by the study team

2016-12-26

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects diagnosed with mild to moderate COPD (GOLD stage I, II and III)-
• 10 pack-year smoking history or greater and ceased to smoke at least for 2 months prior to recruitment
• Subjects taking H2 antagonists, Imodium or loratadine and willing to stop during the study period

You may not qualify if…

• COPD subjects with >80% or <35% predicted
• Current smokers
• Known allergy/sensitivity to quercetin
• Subjects with primary diagnosis of asthma
• Upper respiratory tract infection within two weeks of the screening visit
• Acute bacterial infection requiring antibiotics within two weeks of screening
• Emergency treatment or hospitalization within one month of screening
• Pregnant or lactating mothers
• Women who don't consent to take pregnancy test
• Unwillingness to stop flavonoid supplementation
• Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
• Daily oral steroid treatment, warfarin, cyclosporine (neural, sandimmune), digoxin, fexofenadine, paclitaxel, diltiazem, saquinavir, selected chemotherapeutic agents (etoposide, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir), verapamil, oral glucocorticoids, erythromycin, quinidine
• Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
• Lung cancer history or undergoing chemo- or radiation therapy
• Inflammatory bowel disease
• Child bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.